<DOC>
	<DOC>NCT01737268</DOC>
	<brief_summary>FK949E will be administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change will be evaluated in an open-label manner.</brief_summary>
	<brief_title>Long-term Study of FK949E in Elderly Bipolar Disorder Patients</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Diagnosis of bipolar I or II disorder as specified in the DSMIVTR, with a major depressive episode Able to participate in the study with understanding of and compliance with subject requirements during the study in the investigator's or subinvestigator's opinion Male subjects must agree to take appropriate contraceptive measures with condoms during the study period. Female subjects must be confirmed to have no childbearing potential during the study period Concurrent or previous history of DSMIVTR Axis I disorders, except bipolar disorder, within the last 6 months before informed consent Concurrence of DSMIVTR Axis II disorder that is considered to greatly affect patient's current mental status. The Young Mania Rating Scale (YMRS) total score of 13 points or more. Nine or more mood episodes within the last 12 months before informed consent. Lack of response to at least 6week treatment with at least 2 antidepressants for the current major depressive episode in the investigator's or subinvestigator's opinion The current major depressive episode persisting for more than 12 months or less than 4 weeks before informed consent. History of substance dependence (other than caffeine and nicotine) or alcohol abuse or dependence. Treatment with a depot antipsychotic within the last 49 days before primary registration. Unable to suspend antipsychotics or antidepressants after primary registration Treatment with two or more of mood stabilizers (lithium carbonate and/or sodium valproate) and lamotrigine, if these drugs, except one of either drug, cannot be suspended after primary registration. Unable to suspend antiepileptics (except lamotrigine and sodium valproate), antianxiety agents, hypnotics, sedatives, psychostimulants, antiparkinsonian agents, cerebral ameliorators, antidementia agents, or anorectics, except those specified as conditionallyallowed concomitant drugs, from 7 days before primary registration Electroconvulsive therapy within the last 83 days before primary registration. A possible need of psychotherapy during the study period (unless the therapy has been commenced at least 83 days before primary registration). The Hamilton Depression Rating Scale (HAMD17) suicide score of 3 points or more, history of suicide attempt within the last 6 months before informed consent, or the risk of suicide in the investigator's or subinvestigator's opinion</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>patients</keyword>
	<keyword>Major depressive episode</keyword>
	<keyword>FK949E</keyword>
</DOC>